Expand all sections

Mosunetuzumab

Extended indication

Refractory follicular lymphoma (FL)
Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Mosunetuzumab
Domain

Oncology and Hematology
Reason of inclusion

New medicine (specialité)
Main indication

Indolent non-Hodgkin’s lymphoma
Extended indication

Refractory follicular lymphoma (FL)
Manufacturer

Genentech
Route of administration

Intravenous
Therapeutical formulation

Intravenous drip
Budgetting framework

Intermural (MSZ)
Additional comments 
Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulant.

Registration

Registration route

Centralised (EMA)
Type of trajectory

Accelerated assessment
Submission date

November 2021
Expected Registration

July 2022
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet
Frequency of administration

1 times every 4 weeks
References 
NCT04712097
Additional comments 
Patients will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.